ArticleJournal of dental sciences2026
A scientometric study on research trends and characteristics of medication-related osteonecrosis of the jaw.
Article in Journal of dental sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/purpose: Medication-related osteonecrosis of the jaw (MRONJ) is a debilitating condition characterized by a progressive necrosis of jaw bone in patients who have received anti-resorptive or anti-angiogenic medications. The purpose of this study was to analyze the scientometric characteristics and research trends of MRONJ. Materials and methods: All the papers on MRONJ were comprehensively retrieved from the Scopus database. Results: Among all the 2857 papers on MRONJ, 2251 (78.8 %) were published by stomatologists. The most common medications that cause MRONJ were diphosphonates, zoledronic acid, and denosumab. The MRONJ-related diseases were multiple myeloma, breast cancer, prostate cancer, bone metastasis, diabetes mellitus, and rheumatoid arthritis. Treatment strategies including debridement, antibiotic therapy, conservative treatment, hyperbaric oxygen therapy, low level laser therapy, and platelet-rich fibrin application. A good medical history with emphasis on the use of medication that cause MRONJ, detailed clinical and radiographic evaluations excluding jaw metastasis cancer and osteoradionecrosis, and attention to the patient's signs and symptoms are critical for the correct diagnosis and appropriate treatment. Herein, we also highlight the awareness of early recognition and timely diagnosis and improve the access to care for MRONJ. Conclusion: This scientometric study elucidated the current scenario and research trends of MRONJ, and proposed that multidisciplinary comprehensive management should be conducted to achieve optimal outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.